Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

PURPOSE: Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rit...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Sehn, Laurie H., Goy, Andre, Offner, Fritz C., Martinelli, Giovanni, Caballero, M. Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D., Gaidano, Gianluca, Fayad, Luis E., Buckstein, Rena, Friedberg, Jonathan W., Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, Press, Oliver W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2015
Onderwerpen:
ORIGINAL REPORTS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087315/
https://ncbi.nlm.nih.gov/pubmed/26282650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.2139
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items